Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C

Hepatology

Volumn 50, Issue 2, 2009, Pages 361-368

  Mailliard, Mark E ^a   Capadano, Mary E ^a   Hrnicek, Matthew J ^a   Gilroy, Richard K ^a   Gulizia, James M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; COMORBIDITY; DRUG RESPONSE; EPIDEMIC; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 3A; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LIVER GRAFT; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMISSION; SEROLOGY; VIRUS TRANSMISSION; BLOOD; CROSS INFECTION; GENETICS; GENOTYPE; LIVER; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; UNITED STATES; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CROSS INFECTION; DISEASE OUTBREAKS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER; MALE; MIDDLE AGED; NEBRASKA; NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA, VIRAL; YOUNG ADULT;

EID: 68949180029     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22992     Document Type: Article

References (22)

1. Alter MJ. Transmission of hepatitis C virus - route, dose and titer. N Engl J Med 1994;330:784-786. (Pubitemid 24080228)
2. Seeff LB. Natural history of hepatitis C. HEPATOLOGY 2002;36:S35-S46.
3. Strader DB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
4. Macedo de Oliveira A, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005;142:898-902.
5. Reingold AL. Outbreak investigations - a perspective. Emerg Infect Dis 1998;4:21-27.
6. Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
7. Prati D. Transmission of hepatitis C virus by blood transfusion and other medical procedures: a global review. J Hepatol 2006;45:607-616. (Pubitemid 44316867)
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-355.
9. Macedo de Oliveira A, White KL, Beecham BD, Leschinsky DP, Foley BR, Dockter J, et al. Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients. J Clin Virol 2006;35:21-25. (Pubitemid 43020948)
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
11. Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 2004;57:402-406. (Pubitemid 38446259)
12. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection. JAMA 2000;284:450-456.
13. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med 1999;341:556-562.
14. Freeman AJ, Dore GJ, Law MG, Thorpe M, Overbeck JV, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001;34:809-816. (Pubitemid 32928008)
15. Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patient. HEPATOLOGY 1998;27:2-6. (Pubitemid 28041526)
16. de Lateur RP, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-1624. (Pubitemid 38268950)
17. Castellino S, Lensing S, Riely C, Rai SN, Davila R, Hayden RT, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004;103:2460-2466. (Pubitemid 38392994)
18. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. HEPATOLOGY 1991;14:969-974.
19. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739. (Pubitemid 32488789)
20. Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzongi A, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002;99:4588-4591. (Pubitemid 34627231)
21. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006;13:297-302.
22. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects fibrosis progression in a genotype specific way. Gut 2004;53:406-412. (Pubitemid 38241339)